HUE037109T2 - Endoxifén rák kezelésében történõ alkalmazásra - Google Patents
Endoxifén rák kezelésében történõ alkalmazásraInfo
- Publication number
- HUE037109T2 HUE037109T2 HUE07871563A HUE07871563A HUE037109T2 HU E037109 T2 HUE037109 T2 HU E037109T2 HU E07871563 A HUE07871563 A HU E07871563A HU E07871563 A HUE07871563 A HU E07871563A HU E037109 T2 HUE037109 T2 HU E037109T2
- Authority
- HU
- Hungary
- Prior art keywords
- endoxifen
- cancer
- treatment
- Prior art date
Links
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86042006P | 2006-11-21 | 2006-11-21 | |
| US86078806P | 2006-11-22 | 2006-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE037109T2 true HUE037109T2 (hu) | 2018-08-28 |
Family
ID=39492975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE07871563A HUE037109T2 (hu) | 2006-11-21 | 2007-11-21 | Endoxifén rák kezelésében történõ alkalmazásra |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9333190B2 (enExample) |
| EP (1) | EP2101731B1 (enExample) |
| JP (1) | JP2010510327A (enExample) |
| CA (1) | CA2669913C (enExample) |
| DK (1) | DK2101731T3 (enExample) |
| ES (1) | ES2665917T3 (enExample) |
| HU (1) | HUE037109T2 (enExample) |
| IN (1) | IN2014MN00139A (enExample) |
| PL (1) | PL2101731T3 (enExample) |
| PT (1) | PT2101731T (enExample) |
| WO (1) | WO2008070463A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2101731T (pt) | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| ES2624557T3 (es) * | 2008-12-11 | 2017-07-14 | Besins Healthcare Luxembourg Sarl | Composiciones farmacéuticas transdérmicas que comprenden un SERM |
| SI3228319T1 (sl) | 2011-04-28 | 2020-10-30 | Oncopeptides Ab | Liofiliziran pripravek citotoksičnih dipeptidov |
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| JP6284945B2 (ja) * | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ | メルファランフルフェナミドの凍結乾燥製剤 |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
| DE102015222031A1 (de) | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| US20170304232A1 (en) * | 2016-04-20 | 2017-10-26 | Northwestern University | Endoxifen For Local Transdermal Therapy To The Breast |
| TW201919594A (zh) * | 2017-09-11 | 2019-06-01 | 美商艾陶莎基因有限公司 | 局部用組合物及治療方法 |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| WO2021003433A1 (en) | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| AU2021252229A1 (en) | 2020-04-10 | 2022-10-27 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar I disorder |
| CA3185993A1 (en) | 2020-04-10 | 2021-10-14 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar i disorder |
| US20220296514A1 (en) * | 2021-03-18 | 2022-09-22 | FormuRx Pharmaceuticals Co., Ltd. | Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids |
| IL314075A (en) | 2022-01-12 | 2024-09-01 | Atossa Therapeutics Inc | Compositions of (Z)-endoxifen and methods for their enrichment |
| EP4514327A1 (en) * | 2022-04-26 | 2025-03-05 | Atossa Therapeutics, Inc. | High dose endoxifen formulations and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| ATE252373T1 (de) * | 1994-08-04 | 2003-11-15 | Elan Drug Delivery Ltd | Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung |
| AU736301B2 (en) * | 1996-05-01 | 2001-07-26 | Imarx Therapeutics, Inc. | Methods for delivering compounds into a cell |
| US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for lipid-based drug compounds; preparations, processes and their use |
| WO2008048194A1 (en) | 2006-10-20 | 2008-04-24 | Yesilogluj Aysegul Yildiz | Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder |
| US9637515B2 (en) | 2006-11-06 | 2017-05-02 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| PT2101731T (pt) | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| JP5720881B2 (ja) | 2011-01-31 | 2015-05-20 | 東芝ライテック株式会社 | Ｌｅｄランプ点灯装置および照明装置 |
-
2007
- 2007-11-21 PT PT78715638T patent/PT2101731T/pt unknown
- 2007-11-21 WO PCT/US2007/085443 patent/WO2008070463A2/en not_active Ceased
- 2007-11-21 IN IN139MUN2014 patent/IN2014MN00139A/en unknown
- 2007-11-21 PL PL07871563T patent/PL2101731T3/pl unknown
- 2007-11-21 HU HUE07871563A patent/HUE037109T2/hu unknown
- 2007-11-21 DK DK07871563.8T patent/DK2101731T3/en active
- 2007-11-21 CA CA2669913A patent/CA2669913C/en active Active
- 2007-11-21 ES ES07871563.8T patent/ES2665917T3/es active Active
- 2007-11-21 US US12/515,261 patent/US9333190B2/en active Active
- 2007-11-21 JP JP2009538518A patent/JP2010510327A/ja active Pending
- 2007-11-21 EP EP07871563.8A patent/EP2101731B1/en not_active Revoked
-
2016
- 2016-04-27 US US15/139,687 patent/US10376479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2101731A4 (en) | 2011-04-20 |
| US9333190B2 (en) | 2016-05-10 |
| EP2101731A2 (en) | 2009-09-23 |
| WO2008070463A9 (en) | 2008-09-18 |
| WO2008070463A3 (en) | 2008-11-06 |
| CA2669913C (en) | 2012-09-18 |
| ES2665917T3 (es) | 2018-04-30 |
| CA2669913A1 (en) | 2008-06-12 |
| PT2101731T (pt) | 2018-04-18 |
| US10376479B2 (en) | 2019-08-13 |
| WO2008070463A2 (en) | 2008-06-12 |
| US20100112041A1 (en) | 2010-05-06 |
| US20160346230A1 (en) | 2016-12-01 |
| IN2014MN00139A (enExample) | 2015-06-19 |
| EP2101731B1 (en) | 2018-01-31 |
| DK2101731T3 (en) | 2018-04-16 |
| PL2101731T3 (pl) | 2018-07-31 |
| JP2010510327A (ja) | 2010-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2101731T3 (pl) | Endoksyfen do zastosowania w leczeniu nowotworu | |
| IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| EP2038041A4 (en) | THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER | |
| IL228597A0 (en) | Isoindoline compounds for use in the treatment of cancer | |
| IL199609A0 (en) | Antifolate agent combinations in the treatment of cancer | |
| IL197315A0 (en) | Treatment of cancer | |
| PT3424932T (pt) | Boronoftalidas para utilização terapêutica | |
| EP2144887A4 (en) | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER | |
| PL2320900T3 (pl) | Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych | |
| IL199911A0 (en) | 3-cinnolinecarboxamide derivatives and their use for treating cancer | |
| ZA200709542B (en) | Combination therapy in the treatment of cancer | |
| IL206189A (en) | Compounds for use in cancer treatment | |
| AU2006251169A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
| AU2006251167A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
| IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| IL226363A0 (en) | Compounds and methods for treating cancer | |
| GB0619816D0 (en) | Novel interferon-alpha constructs for use in the treatment of cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
| EP2056839A4 (en) | COMBINED APPROACHES FOR THE TREATMENT OF CANCER | |
| GB0710871D0 (en) | Cancer treatment | |
| IL205339A0 (en) | Compounds and methods for the treatment of cancer | |
| ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| GB0600903D0 (en) | Treatment of cancer | |
| GB0604114D0 (en) | Combinations for the treatment of cancer |